Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PGD | P52209 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL5374586 | 0.79 | LMNA (0.71) | LMNA | |
| Bicarbonate SCHEMBL28942687 | 0.79 | LMNA (0.71) | LMNA | |
| Bicarbonate SCHEMBL28895866 | 0.79 | LMNA (0.71) | LMNA | |
| SCHEMBL7837815 | 0.79 | ALDH1A1 (0.44) | — | |
| SCHEMBL607460 | 0.79 | ALDH1A1 (0.44) | — | |
| SCHEMBL7846935 | 0.79 | ALDH1A1 (0.44) | — | |
| SCHEMBL28846520 | 0.78 | MMP8 (0.40) | LMNASMN1; SMN2 | |
| Acetic Acid SCHEMBL23907968 | 0.77 | LMNA (0.67) | LMNA | |
| Acetic Acid SCHEMBL222953 | 0.77 | LMNA (0.67) | LMNA | |
| Bicarbonate SCHEMBL9453328 | 0.77 | LMNA (0.67) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426617-B2 | Asymmetric hydrogenation of alkenes using chiral iridium complexes | DSM IP ASSETS B.V. (NL) | 2013-04-23 | — | — | US | disclosed |
| EP-1828159-B1 | ASYMMETRIC HYDROGENATION OF ALKENES USING CHIRAL IRIDIUM COMPLEXES | DSM IP ASSETS BV (NL) | 2011-08-17 | — | — | EP | disclosed |
| US-20080039638-A1 | Asymmetric Hydrogenation of Alkennes Using Chiral Iridium Complexes | DSM IP ASSETS B.V. (NL) | 2008-02-14 | — | — | US | disclosed |
| EP-1828159-A1 | ASYMMETRIC HYDROGENATION OF ALKENES USING CHIRAL IRIDIUM COMPLEXES | DSMIP Assets B.V. (NL) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006066863-A1 | ASYMMETRIC HYDROGENATION OF ALKENNES USING CHIRAL IRIDIUM COMPLEXES | DSM IP ASSETS B.V. (NL) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039638-A1 | Asymmetric Hydrogenation of Alkennes Using Chiral Iridium Complexes | SQLE, FADS1, FADS2 | LMNA 4536/4885SMN1; SMN2 3847/4885PGD 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.